4D Molecular Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 12.78 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 706.02M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company’s lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is...